Leadership

Leadership

Jeff Kraws

CEO

Gali Guzikevich

Director of Quality Assurance

John Driscoll

CFO

Andrew Salzman

President, Drug Development

Jeff Kraws

CEO

  • 20 year Wall St healthcare banker executive and widely followed analyst
  • Co-founder, CEO, Crystal Research Associates
  • Director, Synthetic Biologic (NYSE: SYN)
  • Chairman, Avivagen (TSXV: VIV)
  • Consistently ranked among Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades and ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks
  • Other financial positions include healthcare banker with Piper Sandler, principal at Investor Relations Group, and managing director Gruntal Ryan Beck and Everen Securities (now Wachovia Bank)

Gali Guzikevich

Director of Quality Assurance

  • 15 years pharmaceutical industry experience
  • Doctoral degree in structural biology and chemistry at the Weizmann Institute of Science
  • 3 peer-reviewed publications in Nature
  • Quality assurance and regulatory affairs expert, specialty in international pharmaceutical guidelines: Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP)
  • Former, 8-year, global GMP QA Senior Director, Teva Pharmaceuticals


John Driscoll

CFO

  • 10 years senior experience in financial strategy and implementation, accounting and auditing, most recently as Chief Audit Executive for 13,000 employee fintech platform, Finastra
  • Former senior audit and anti-fraud positions with Fundtech, CIT, AIG, Phillip Morris, and The New York County District Attorney’s Office

Andrew Salzman

President, Drug Development

  • Harvard-trained, global researcher with 165 peer review publications, 12 US patent awards
  • Founder, CEO or Chairman of Kalytera Therapeutics, Claritas Pharma, Herring Creek, Pharma, AOX Pharma, Chilmark Labs, Quitsa Pharma
  • Funding for 135 NIH, DARPA, and BARDA grants totaling $160 million
  • Ischemia-reperfusion injury, intestinal mucosal biology, pulmonary arterial hypertension, autoimmune disease, and mechanisms of pro-inflammatory gene expression
  • Yale undergraduate, Harvard Medical School
  • Basic scientific discoveries:
  • Enhancer region of the human inducible nitric oxide synthase gene
  • Principal microbial protein (flagellin) that activates inflammation in epithelial cells
  • Enzyme in bacteria that detoxifies nitric oxide (flavohemoglobin)
  • First soluble nitric oxide donor that selectively lowers pulmonary hypertension
  • First nitric oxide synthase inhibitor selective for the inducible isoform
  • First ultrapotent selective A1 agonist
  • First nanomolar-potent PARP inhibitor


Share by: